Sunitinib Reverse Multidrug Resistance in Gastric Cancer Cells by Modulating Stat3 and Inhibiting P-gp Function

Cell Biochemistry and Biophysics

Volumn 67, Issue 2, 2013, Pages 575-581

  Zhang, Ye ^a   Wang, Qiong ^b  

^a Soochow University   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; Multidrug resistance; P gp; Stat3; Sunitinib

Indexed keywords

ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; PYRROLE DERIVATIVE; RHODAMINE 123; STAT3 PROTEIN; SUNITINIB; VINCRISTINE;

ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; HUMANS; INDOLES; P-GLYCOPROTEIN; PYRROLES; RHODAMINE 123; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; VINCRISTINE;

EID: 84886585863     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9544-5     Document Type: Article

References (34)

1. Murray, C. J., & Lopez, A. D. (1997). Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet, 349, 1498-1504.
2. Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., van de Velde, C. J., Nicolson, M., et al. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine, 355, 11-20.
3. Rivera, F., Vega-Villegas, M. E., & Lopez-Brea, M. F. (2007). Chemotherapy of advanced gastric cancer. Cancer Treatment Reviews, 33, 315-324.
4. Szakacs, G., Paterson, J. K., Booth-Genthe, C., & Gottesman, M. M. (2006). Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery, 5, 219-234.
5. Hong, L., Piao, Y., Han, Y., Wang, J., Zhang, X., Du, Y., et al. (2005). Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2. Molecular Cancer Therapeutics, 4, 1936-1942.
6. Zhu, W., Xu, H., Zhu, D., Zhi, H., Wang, T., Wang, J., et al. (2012). miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemotherapy and Pharmacology, 69, 723-731.
7. Xia, L., Zhang, D., Du, R., Pan, Y., Zhao, L., Sun, S., et al. (2008). miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. International Journal of Cancer, 123, 372-379.
8. Huang, S., Chen, M., Shen, Y., Shen, W., Guo, H., Gao, Q., et al. (2012). Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Letters, 315, 198-205.
9. Hu, W. Q., Peng, C. W., & Li, Y. (2009). The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancer. Journal of Experimental and Clinical Cancer Research, 28, 144-149.
10. Abrams, T. J., Lee, L. B., Murray, L. J., Pryer, N. K., & Cherrington, J. M. (2003). SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Molecular Cancer Therapeutics, 2, 471-478.
11. Pan, F., Tian, J., Zhang, X. C., & Pan, Y. Y. (2010). Inhibitory effect of sunitinib on EGFR TKI-resistant humannon-small cell lung cancer cell line A549 and its mechanism. Chinese Pharmacological Bulletin, 8, 91-95.
12. Anglesio, M. S., George, J., & Kulbe, H. (2011). IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clinical Cancer Research, 17, 2538.
13. Saito, Y., Tanaka, Y., & Aita, Y. (2012). Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD. American Journal Physiology Endocrinology Metabolism, 302, E615-E625.
14. Shukla, S., Robey, R. W., Bates, S. E., & Ambudkar, S. V. (2008). Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metabolism and Disposition, 37, 359-365.
15. Dai, C. L., Liang, Y. J., Wang, Y. S., et al. (2009). Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Letters, 279, 74-83.
16. Cai, X. J., Fan, D. M., & Zhang, X. Y. (1994). Establishment and biological characteristics of MDR human gastric cancer cell line. Chinese Journal of Clinical Oncology, 2, 67-71.
17. Chen, L. M., Wu, X. P., Ruan, J. W., et al. (2004). Screening novel, potent multidrugresistant modulators from imidazole derivatives. Oncology Research, 14, 355-362.
18. Morgillo, F., Martinelli, E., Troiani, T., Orditura, M., De Vita, F., & Ciardiello, F. (2011). Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. PLoS ONE, 6, e28841.
19. Guo, X. L., Ma, N. N., Wang, J., Song, J. R., Bu, X. X., Cheng, Y., et al. (2008). Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer, 8, 375.
20. Wang, T. C., Wei, J. Z., Guo, C. S., Zhang, H. B., & Fan, H. X. (2010). Design, synthesis and anti-proliferative studies of a novel series of indirubin derivatives. Chinese Chemical Letters, 21, 1407-1410.
21. Zhang, Y. F., Shi, Y. Q., Li, X. H., Du, R., Luo, G. H., Xia, L., et al. (2008). Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp. Cancer Biology and Therapy, 7, 540-546.
22. Xin, H., Zhang, C. Y., & Herrmann, A. (2009). Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Research, 69, 2506-2513.
23. Di Lauro, L., Giacinti, L., Arena, M. G., Sergi, D., Fattoruso, S. I., Giannarelli, D., et al. (2009). Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 28, 34-39.
24. Gottesman, M. M., Fojo, T., & Bates, S. E. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer, 2, 48-58.
25. Chen, Q., Zhou, J., Jiang, C. F., & Chen, J. (2010). Reversal of P-glycoprotein-mediated multidrug resistance in SGC7901/VCR cells by PPARγ activation by troglitazone. Journal of Huazhong University of Science and Technology, 30, 326-331.
26. Zhang, Y., Qu, X. J., Liu, Y. P., Yang, X. H., Hou, K. Z., Teng, Y. E., et al. (2009). Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR. Chinese Journal of Cancer, 28, 97-99.
27. Zhu, W., Shan, X., Wang, T., Shu, Y., & Liu, P. (2010). miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. International Journal of Cancer, 127, 2520-2529.
28. Fang, S., Zhu, W., Zhang, Y., Shu, Y., & Liu, P. (2012). Paeoniflorin modulates multidrug resistance of a human gastric cancer cell line via the inhibition of NF-κB activation. Molecular Medicine Reports, 5, 351-356.
29. Coburger, C., Lage, H., Molnár, J., Langner, A., & Hilgeroth, A. (2010). Multidrug resistance reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors. Journal of Pharmacy and Pharmacology, 62, 1704-1710.
30. Bang, Y. J., Kang, Y. K., Kang, W. K., Boku, N., Chung, H. C., Chen, J. S., et al. (2011). Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Investigational New Drugs, 29, 1449-1458.
31. Lage, H. (2003). Molecular analysis of therapy resistance in gastric cancer. Digestive Diseases, 21, 326-338.
32. Mi, Y. J., Liang, Y. J., Huang, H. B., et al. (2010). Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Research, 70, 7981-7991.
33. Tao, L. Y., Liang, Y. J., Wang, F., Chen, L. M., Yan, Y. Y., Dai, C. L., et al. (2009). Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemotherapy and Pharmacology, 64, 961-969.
34. Santandreu, F. M., Valle, A., Oliver, J., & Roca, P. (2011). Resveratrol potentiates the cytotoxic oxidative stress induced by chemotherapy in human colon cancer cells. Cellular Physiology and Biochemistry, 28, 219-228.